Working with Meridian IT, Oxford Cancer Biomarkers are combining leading-edge diagnostics with IBM® PowerAI Vision to improve outcomes for cancer patients
From 503T274N3D 503T274N3D on April 2nd, 2019
Predicting which patients with stage II colorectal cancer will suffer a recurrence after surgery is difficult. However, many are routinely prescribed chemotherapy, even though it may cause severe side effects. In some patients these can be fatal. Oxford Cancer Biomarkers worked with Meridian IT to apply IBM® PowerAI Vision to identify novel diagnostic biomarkers in tumor microenvironments, with the potential to enhance early diagnosis and treatment decisions.